According to a new French study, "Anakinra", which is devoted to rheumatic diseases, gave "encouraging" results in treating severe forms of Coronavirus, "Covid 19", by reducing the risk of death and the necessity of placing the respirator in intensive care.
According to the researcher and the doctor, Thomas Hoyt, and his colleagues, from the Paris Saint-Joseph hospital group, the drug was given to 52 patients with severe form of Corona, by injection, for 10 days. The French medical team recorded a significant decrease in the risk of death and admission to intensive care to receive artificial respiration.
"The significant reduction in mortality associated with the use of Anakinra in this study is encouraging in these difficult times," said rheumatologist, Randy Crohn of the University of Alabama. In the specialized journal "The Lancet Rematology", "favorable safety features" of this medication, well known to rheumatologists, were emphasized.
While a quarter of the patients treated with "anakina" died, or entered intensive care, the proportion reached about 73% for those who did not undergo this vital treatment. And in the group that received the drug, a rapid decrease in the need for oxygen was observed, after 7 days of treatment.
"Waiting for more on the results of such tests, Anakinra offers hope to those who were highly affected by Covid 19," said Kroon.